Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Not Confirmed
Not Confirmed
27 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
Oligo Chemistry & Ther...Oligo Chemistry & Therapeutics 2024
Webinar
Not Confirmed
27 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
28 Apr 2022
// BUSINESSWIRE
Details:
DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: DLP-114
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.
Brand Name : DLP-114
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Details:
If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Brand Name: DLP-160
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.
Brand Name : DLP-160
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2022
Details:
Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.
Lead Product(s): Tizanidine HCl
Therapeutic Area: Musculoskeletal Brand Name: DLP-208
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: National Institutes of Health
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 16, 2021
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...
Brand Name : DLP-208
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?